Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology.

Weiss RD, Potter JS, Provost SE, Huang Z, Jacobs P, Hasson A, Lindblad R, Connery HS, Prather K, Ling W.

Contemp Clin Trials. 2010 Mar;31(2):189-99. doi: 10.1016/j.cct.2010.01.003. Epub 2010 Jan 29.

2.

The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.

Nielsen S, Hillhouse M, Weiss RD, Mooney L, Sharpe Potter J, Lee J, Gourevitch MN, Ling W.

Am J Addict. 2014 Jul-Aug;23(4):343-8. doi: 10.1111/j.1521-0391.2013.12105.x. Epub 2013 Sep 24.

3.

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W.

Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7.

4.

Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?

Weiss RD, Griffin ML, Potter JS, Dodd DR, Dreifuss JA, Connery HS, Carroll KM.

Drug Alcohol Depend. 2014 Jul 1;140:118-22. doi: 10.1016/j.drugalcdep.2014.04.005. Epub 2014 Apr 24.

5.

Short term health-related quality of life improvement during opioid agonist treatment.

Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser YI, Ling W, Schackman BR.

Drug Alcohol Depend. 2015 Dec 1;157:121-8. doi: 10.1016/j.drugalcdep.2015.10.009. Epub 2015 Oct 25.

6.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD.

Pain. 2013 Aug;154(8):1442-8. doi: 10.1016/j.pain.2013.05.004. Epub 2013 May 7.

7.

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D; Buprenorphine Study Protocol Group.

Addiction. 2005 Aug;100(8):1090-100. Erratum in: Addiction. 2006 Sep;101(9):1374.

8.

Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.

Lucas GM, Young A, Donnell D, Richardson P, Aramrattana A, Shao Y, Ruan Y, Liu W, Fu L, Ma J, Celentano DD, Metzger D, Jackson JB, Burns D; HPTN 058 study group.

Drug Alcohol Depend. 2014 Sep 1;142:139-45. doi: 10.1016/j.drugalcdep.2014.06.013. Epub 2014 Jun 19.

9.

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22-32. doi: 10.1097/QAI.0b013e318209751e.

10.

Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Dreifuss JA, Griffin ML, Frost K, Fitzmaurice GM, Potter JS, Fiellin DA, Selzer J, Hatch-Maillette M, Sonne SC, Weiss RD.

Drug Alcohol Depend. 2013 Jul 1;131(1-2):112-8. doi: 10.1016/j.drugalcdep.2012.12.010. Epub 2013 Jan 18.

11.

Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.

Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S83-90. doi: 10.1097/QAI.0b013e31820bc9a5.

12.

Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.

Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, Srisarajivakul EN, Dodd DR, Dreifuss JA, McHugh RK, Carroll KM.

Drug Alcohol Depend. 2015 May 1;150:112-9. doi: 10.1016/j.drugalcdep.2015.02.030. Epub 2015 Mar 6.

13.

Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.

Mooney LJ, Nielsen S, Saxon A, Hillhouse M, Thomas C, Hasson A, Stablein D, McCormack J, Lindblad R, Ling W.

Contemp Clin Trials. 2013 Mar;34(2):196-204. doi: 10.1016/j.cct.2012.11.002. Epub 2012 Nov 16.

14.

Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.

Griffin ML, Dodd DR, Potter JS, Rice LS, Dickinson W, Sparenborg S, Weiss RD.

Am J Drug Alcohol Abuse. 2014 Mar;40(2):157-62. doi: 10.3109/00952990.2013.842241. Epub 2013 Nov 12.

15.

Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG.

JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302.

PMID:
25330017
16.

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA.

J Gen Intern Med. 2012 Jun;27(6):669-76. doi: 10.1007/s11606-011-1962-8. Epub 2012 Jan 4.

17.

The multi-site prescription opioid addiction treatment study: 18-month outcomes.

Potter JS, Dreifuss JA, Marino EN, Provost SE, Dodd DR, Rice LS, Fitzmaurice GM, Griffin ML, Weiss RD.

J Subst Abuse Treat. 2015 Jan;48(1):62-9. doi: 10.1016/j.jsat.2014.07.009. Epub 2014 Aug 2.

18.

A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.

Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE.

J Addict Med. 2014 May-Jun;8(3):176-82. doi: 10.1097/ADM.0000000000000035.

PMID:
24695018
19.

Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.

Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE.

Addiction. 2010 Sep;105(9):1616-24. doi: 10.1111/j.1360-0443.2010.03001.x. Epub 2010 Jul 12.

20.

Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.

Egan JE, Netherland J, Gass J, Finkelstein R, Weiss L; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S46-53. doi: 10.1097/QAI.0b013e3182097561.

PMID:
21317594

Supplemental Content

Support Center